"Our project is innovative in its use of advanced epigenetic techniques combined with a novel preclinical model of PDAC survivorship," Dr. Arneson-Wissink said. "Together, these tools allow us to ...

Cancer cachexia impacts almost 90% of people living with pancreatic cancer. Learn more about this condition in this Q&A with Nicolas Clifford, PanCAN’s manager of research and education communication.

Cachexia, defined as a loss of body weight, fat, and muscle mass that occurs in patients with chronic diseases, including cancer, remains a notable clinical challenge. With limited viable treatment ...

Until recently, the root cause of cachexia was identified as the inflammatory mediators produced either by the tumour itself ...

A private US biotechnology company, Endevica Bio develops peptide therapeutics and peptidomimetics that target GPCR biology, ...

Kalohexis, a newly created biotechnology company to advance the clinical development of a portfolio of drug candidates harnessing the melanocortin (MC) system for the treatment of metabolic disorders ...

Cancer cachexia is a multifactorial syndrome marked by a severe loss of body weight due primarily to the wasting of skeletal muscle and adipose tissue. This syndrome is often accompanied by systemic ...

The dietary supplement melatonin does not improve the symptoms of cachexia in patients with advanced cancer, according to a study published online February 25 in the Journal of Clinical Oncology.

Pfizer researchers say they are developing a drug that might counteract a condition that leads to the death of cancer patients within a year of its diagnosis. Photo by Stephanie Lecocq/EPA-EFE Sept.

PH284 nasal spray increased hunger in cancer cachexia patients, showing a 71% improvement in subjective hunger scores compared to baseline. The phase 2A study demonstrated PH284's safety, with no ...

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the cancer cachexia therapeutics market and it is poised to grow by USD 568.85 million during 2019-2023, progressing at a CAGR of 6% during the ...